Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295875 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ALT-801 in the Treatment of Obesity
A Phase 2 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
NCT05295875: Completed Phase 2 study, sponsored by Altimmune.
NCT05295875 is a Phase 2 study that has completed, run by Altimmune. The registered enrollment target is 391 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (194% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05295875, a Phase 2 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Interventions
- OTHER Placebo
- DRUG ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
What the finished NCT05295875 record still lists
NCT05295875 is an interventional study that assigns participants to a tested intervention. The registered 391 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (194% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05295875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05295875 about?
NCT05295875 is a clinical study titled "Efficacy and Safety of ALT-801 in the Treatment of Obesity". This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
What is the current status of trial NCT05295875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2022-03-31. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05295875?
The interventions under investigation include: Placebo (OTHER), ALT-801 (DRUG).
Who is sponsoring clinical trial NCT05295875?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05295875's enrollment target sits among peer trials
391 106th of 2000 higher than 1,895 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI